# Compass says depression drug has long-lasting benefits

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-07 22:29 UTC · Category: Business · Sources: 6 · Current Velocity: 4.29

## Executive Summary
Compass Pathways reports positive six-month data for its psilocybin-based depression treatment, fueling market confidence and future filing plans.

## Intelligence Brief
Compass Pathways has released results from its second Phase 3 clinical trial involving the investigational drug COMP360. Data indicates that the psilocybin treatment maintained depression-related benefits for participants through a 26-week period.


Coverage from outlets including STAT, Endpoints News, and Business Wire emphasizes the durability and rapid onset of the drug's effects. Financial analysis and market reporting from Moomoo, BTIG, and Psychedelic Alpha highlight positive shifts in company stock performance and the maintenance of a buy rating for the firm.


Attention now shifts to the company's regulatory timeline. Reported plans include a year-end filing with health authorities, with the organization looking toward a potential launch in the first half of 2027.

## Verified Facts & Key Claims
### What is the duration of the benefits reported?
Clinical trial data confirms that benefits were sustained through 26 weeks.

### When does Compass Pathways anticipate a product launch?
The company is targeting a launch in the first half of 2027.

### How have analysts responded to the data?
BTIG has maintained a buy rating for Compass Pathways, and shares have gained following the announcement.

## Key People, Organizations & Locations
Weeks, Compass, Compass Pathways Announces Six-Month Data, Second Phase, Trial Confirming Rapid and Durable Profile, Compass Pathways Shares Gain, Positive Late-Stage Trial Data for Depression Treatment, Compass Closes Out Phase, COMP006 Data Eyes, COMP360 Psilocybin Sustains Depression Benefit Through

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| HCPLive | COMP360 Psilocybin Sustains Depression Benefit Through 26 Weeks | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMijAFBVV95cUxNeGhDaDVZQ2MtQkhWZ0xKRWVza3ZZZHZuVWhjVHQ0RDBRdTlBNXBzTFJIbUVabmh1M0VOMWhqd3drNzBQc1F2YTNHLUFzUXpWQkY1SWFWTXJPUHBXNTF5OXlQVVNXVElpY3Y2X0N4TmE0N1VQb0wxRjFLMjFwV2d2WmpfWXZBQlRqRm5ucg?oc=5) |
| Moomoo | Compass Pathways Is Maintained at Buy by BTIG | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxNMkNJTEN4M243T1ZCeFBnWG95aEFQLWdQcWtzZ0VUenpMSFIxTklZeWVVQVFZbGE2blpSTGRmS3QwYUprbnVWa2ZCZEdvd25mSjcwdFd6TklMVlJockhvQS1XLXZ5WVZTTzVldW85NGZVZ0tWcXR4QjZJTmE3Qm5FcHJHVnpmdGNMRW1WM3FsZDA?oc=5) |
| Business Wire | Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMi8wFBVV95cUxNVkFqbkxFeVV3bzNBeHhodHIxYUliZ3E2WlVpanpHUEdpQjR4NUstQ2N6dHp0Q0RDZi1ycXJDVlhkeV9uUmtZXzNSZk1pdFUzNVpkOFNaZVdmb2RiODdjLVNrUHl4YlZraTNWRktfVzZWMUZXZUxRcU9PckVJVlQtZ2M5OURscXItU3ZsakZSVjBlUHdaN3FjNDBXbnEzWE1BZUpublpscEFPMy05U2VGdGFha0xRV2U4UjJYbmw4SG8zY3U4Rkk1SVpkQU15ODVoLTBsdW1YNnhZWnczUUFmM2l0dzdnTktGeW1ISkZUMEpPMk0?oc=5) |
| Moomoo | Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxNdklZaUM0aHA5MWVwemZMd3VtQ0JQQUUzd3lFZjlndnYtLTBnbENvNjhpLXhUX1F2ME43aml6Tkc4M2J1OHF3WEI3R1hLT2QzM3pmdW03T0VXZmFob1lyNGIzTC1kMkVOeEdEeWM1VWJrcUU4U1doYmF6X0laNzVMYlJkcWpZT3VZNTQ2aVFaV1dUVUhzejVFT2hVc2hUVFN3OVRWYTZBaw?oc=5) |
| Psychedelic Alpha | Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxQd3d4ckQ3VUFFdGF5OGlieUNURkpSNEhiWGh5bVdBRU1Vc3ctbjh6ZlpqNHZSVFlUSTUyeU5kQV83eUp1MFEyejZLd3kzUFJVX2QxalZnT2ZnWnUwM1dNRVU2WGcyMnVRd2lXQ00yeF9FR2U4cHdrUDhDZHJfelk4TS0wazZqZ0hjTlhBSklXalNiMmpHcHZlZTA4S2dQTFZaMnNMMHVobw?oc=5) |
| Endpoints News | Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxQLXQtUFJ6RWRvZWFHR3lYX0dPcE1oMDZya2tQVWVHdmtJSjQ5M21oOEVqUFNSUE1mMXh2VURzck5xdDNrdmZ0eW45ZDRGRWVlZTRQTGcxdEl4YWxlSWFRcmdycV9oSG5DZXk2bmo2Tzl4RWx1Zkt6cFg4MWx1UVM0Rmt3TVVrLTV1bmdYaDE3VVh1bVUxSTVDcHozU0hyYTQxQWZ4dDR0RXFxRzJTV0lBR1pn?oc=5) |
| STAT | Compass says depression drug has long-lasting benefits | 2026-07-07 15:06 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSW1qNjBQWWF2VFZyQjZ6MWd2bUFEVUVSOXFwVy1DM05uOGczanhCTFBiaVlpY2xrVWh3cWM4LXZJY1g2Z3BEQ0UzMGpBa25BaUhKbGpSWW1LN1VMdm1GNTB0dF9QQlQtWDRBRGFJZ1VzX2lETUtyS3ZIX3VuQkx5MFpWYW5YYk5hMy0yQktvNkdSamwtQnRJcVFNUnlDeUIza0Nid0hCVF8tVW8?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-07/compass-says-depression-drug-has-long-lasting-benefits*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*